Bayer 11726 : Essai de phase 2 évaluant l’efficacité d’un traitement par BAY 73-4506 chez des patients ayant un cancer des cellules rénales, métastatique non résécable. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A phase II uncontrolled study of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)

• Pays France
• Organes Rein
• Spécialités Chimiothérapie

Estudio de fase III, aleatorizado y en doble ciego, de evaluación de la eficacia y la seguridad de sorafenib en comparación con placebo en el cáncer de tiroides diferenciado refractario al yodo radiactivo localmente avanzado/metastático A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer The primary objective of this phase III study in subjects with differentiated thyroid cancer (papillary, follicular, Hurthle cell carcinoma) who are refractory to radioactive iodine treatment is to co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07) The main objective is the feasibility of the adjuvant chemotherapy which has gained the best results when combined with radiotherapy so far. The present protocol is primarily to determine the number o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors Investigate the efficacy of a combination of BAY 60 4552 and vardenafil in men with ED and insufficient response to standard therapy with 20 mg vardenafil taken as needed (prn) during the 4 week open-...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase IIb safety and efficacy study of different oral doses of BAY 94-8862 in subjects with worsening chronic heart failure and left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone Primary objective of the study is to investigate efficacy and safety of different oral doses of BAY 94-8862 given once daily over 90 days

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Effectiveness and safety of riociguat in patients with sclerosis of the skin The primary objective of this study is to assess the efficacy of riociguat administered 3 times a day (TID) as compared with placebo in terms of change in the mRSS from baseline to Week 52.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double blinded, placebo controlled, pilot study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the investigational drug BAY 1067197 in patients with chronic heart failure The primary objective of this study is to investigate the safety and tolerability of a multiple dose 7 day once-daily treatment of BAY 1067197 versus a 7 day treatment of placebo in patients with chro...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

To examine the discontinuation rates in women 18 to 35 years of age using LCS12 compared with discontinuation rates in women using the etonogestrel subdermal implant over 12 months. Additionally bleeding patterns, user satisfaction and adverse event profile will be assessed The primary objective is to demonstrate that discontinuation rates in women (ages 18-35 years inclusive) using LCS12 are not higher than those seen in women using ENG subdermal implant over a period o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Riociguat single -dose study measuring of blood flow in lungs with high blood pressure associated with heart failure The objective of the present study is to evaluate the acute hemodynamic effects, safety, and pharmacokinetics of Riociguat in patients with PH associated with diastolic heart failure.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiectomy or are receiving a LHRH analogue The primary objective of this phase II study in castration-resistant metastatic prostate cancer patients who have had orciectomy or are receiving an LHRH analogue is to demonstrate a prolonged progres...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune